CY1115004T1 - Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ - Google Patents

Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ

Info

Publication number
CY1115004T1
CY1115004T1 CY20141100246T CY141100246T CY1115004T1 CY 1115004 T1 CY1115004 T1 CY 1115004T1 CY 20141100246 T CY20141100246 T CY 20141100246T CY 141100246 T CY141100246 T CY 141100246T CY 1115004 T1 CY1115004 T1 CY 1115004T1
Authority
CY
Cyprus
Prior art keywords
aggiotacin
pharmaceutical combinations
receptor components
water inhibitor
inhibitor
Prior art date
Application number
CY20141100246T
Other languages
English (en)
Inventor
Lili Feng
Sven Erik Godtfredsen
Piotr Karpinski
Paul Allen Sutton
Mahavir Prashad
Michael J Girgis
Bin Hu
Yugang Liu
Thomas J Blacklock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115004(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1115004T1 publication Critical patent/CY1115004T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ένας ειδικός συνδυασμός, ένα συνδεδεμένο πρόδρομο-φάρμακο ή μια ένωση που είναι ανταγωνιστής των υποδοχέων αγγειοτασίνης και ένας NEPi χρησιμοποιούνται στη θεραπευτική αντιμετώπιση της υπέρτασης.
CY20141100246T 2005-11-09 2014-03-31 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ CY1115004T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73509305P 2005-11-09 2005-11-09
US73554105P 2005-11-10 2005-11-10
US78933206P 2006-04-04 2006-04-04
US82208606P 2006-08-11 2006-08-11
EP06827689.8A EP1948158B1 (en) 2005-11-09 2006-11-08 Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor

Publications (1)

Publication Number Publication Date
CY1115004T1 true CY1115004T1 (el) 2016-08-31

Family

ID=37908343

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20141100246T CY1115004T1 (el) 2005-11-09 2014-03-31 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CY2016014C CY2016014I1 (el) 2005-11-09 2016-05-18 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CY20201100963T CY1123531T1 (el) 2005-11-09 2020-10-13 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεα αγγειοτενσινης και ενος αναστολεα νερ
CY2021003C CY2021003I2 (el) 2005-11-09 2021-01-14 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεα αγγειοτενσινης και ενος αναστολεα νερ

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2016014C CY2016014I1 (el) 2005-11-09 2016-05-18 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CY20201100963T CY1123531T1 (el) 2005-11-09 2020-10-13 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεα αγγειοτενσινης και ενος αναστολεα νερ
CY2021003C CY2021003I2 (el) 2005-11-09 2021-01-14 Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεα αγγειοτενσινης και ενος αναστολεα νερ

Country Status (36)

Country Link
US (11) US8877938B2 (el)
EP (3) EP3685833A1 (el)
JP (3) JP4824754B2 (el)
KR (2) KR101549318B1 (el)
CN (2) CN102702119B (el)
AR (1) AR057882A1 (el)
AU (1) AU2006311481B2 (el)
BR (2) BR122013025375B8 (el)
CA (1) CA2590511C (el)
CY (4) CY1115004T1 (el)
DK (2) DK2340828T3 (el)
EC (1) ECSP14019136A (el)
ES (2) ES2449765T3 (el)
FR (2) FR16C0018I2 (el)
GT (1) GT200700055A (el)
HK (2) HK1121371A1 (el)
HR (2) HRP20140274T1 (el)
HU (3) HUE050870T2 (el)
IL (2) IL184027A (el)
JO (1) JO3492B1 (el)
LT (3) LT2340828T (el)
LU (1) LUC00195I2 (el)
MA (1) MA30128B1 (el)
MX (1) MX2007008075A (el)
MY (1) MY145462A (el)
NO (3) NO337288B1 (el)
NZ (2) NZ600626A (el)
PE (2) PE20070803A1 (el)
PL (1) PL1948158T3 (el)
PT (2) PT2340828T (el)
RU (1) RU2503668C2 (el)
SG (1) SG10201402055YA (el)
SI (2) SI1948158T1 (el)
TN (1) TNSN07264A1 (el)
TW (2) TWI418348B (el)
WO (1) WO2007056546A1 (el)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) * 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
JP5653218B2 (ja) 2007-11-06 2015-01-14 ノバルティス アーゲー アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
US8212052B2 (en) 2007-12-11 2012-07-03 Theravance, Inc. Dual-acting benzoimidazole antihypertensive agents
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
EP2334651A2 (en) 2008-07-24 2011-06-22 Theravance, Inc. Dual-acting antihypertensive agents
AU2010251967B9 (en) * 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
US7956054B2 (en) 2009-07-07 2011-06-07 Theravance, Inc. Dual-acting pyrazole antihypertensive agents
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
EP2281558A1 (en) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors
JO2967B1 (en) * 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
AU2011326622B2 (en) 2010-11-10 2014-12-18 Theravance Biopharma R&D Ip, Llc Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) * 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2817368C (en) 2010-12-15 2019-12-31 Theravance, Inc. Neprilysin inhibitors
AR084290A1 (es) 2010-12-15 2013-05-08 Theravance Inc Inhibidores de neprilisina, metodos para su preparacion e intermediarios utilizados en los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por la inhibicion de nep
ES2582640T3 (es) 2011-02-17 2016-09-14 Theravance Biopharma R&D Ip, Llc Derivados aminobutíricos sustituidos como inhibidores de neprilisina
US8449890B2 (en) 2011-02-17 2013-05-28 Theravance, Inc. Neprilysin inhibitors
BR112013029199B1 (pt) 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
ES2699773T3 (es) 2011-05-31 2019-02-12 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089954A1 (es) 2012-02-15 2014-10-01 Theravance Inc Forma cristalina del ester 5-metil-2-oxo-[1,3]dioxol-4-ilmetilico del acido (2s,4r)-5-bifenil-4-il-2-hidroximetil-2-metil-4-[(1h-[1,2,3]triazol-4-carbonil)amino]pentanoico
WO2013148768A1 (en) 2012-03-28 2013-10-03 Theravance, Inc. Crystalline forms of (r)-3-[n-(3'-chlorobiphenyl-4-ylmethyl)-n'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester
EP2649996A1 (en) * 2012-04-11 2013-10-16 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of sartans like telmisartan with beta blockers
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
PT2864292T (pt) 2012-06-08 2017-07-10 Theravance Biopharma R&D Ip Llc Inibidores de neprisilina
US9126956B2 (en) 2012-08-08 2015-09-08 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CN108685889A (zh) 2012-08-24 2018-10-23 诺华股份有限公司 用于治疗特征为心房增大或重构的疾病的nep抑制剂
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CA2902456A1 (en) 2013-03-05 2014-09-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
ES2767084T3 (es) 2013-08-26 2020-06-16 Novartis Ag Nuevo uso
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
RU2016135057A (ru) 2014-01-30 2018-03-12 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Производные 5-бифенил-4-гетероарилкарбониламинопентановой кислоты в качестве ингибиторов неприлизина
MX2016009760A (es) 2014-01-30 2016-11-08 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina.
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
LT3218351T (lt) 2014-11-14 2019-09-25 Zentiva K.S. Ahu-377 farmaciniu požiūriu priimtinų formų gavimo, atskyrimo ir gryninimo būdas
CN110922366B (zh) 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
WO2016051393A2 (en) * 2014-12-26 2016-04-07 Crystal Pharmatech Inc. Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105982891A (zh) * 2015-01-30 2016-10-05 王召印 阿利沙坦脂和脑啡肽酶抑制剂或其前药的药物组合物
US10562866B2 (en) * 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
MY187899A (en) 2015-02-11 2021-10-27 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
CN105985225A (zh) * 2015-02-12 2016-10-05 博瑞生物医药（苏州）股份有限公司 一种lcz-696及其中间体的制备方法
CN105884644B (zh) * 2015-02-15 2020-06-09 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐优势形态及其制备方法
HUE052732T2 (hu) 2015-02-19 2021-05-28 Theravance Biopharma R&D Ip Llc (2R,4R)-5-(5'-klór-2'-fluorbifenil-4-il)-2-hidroxi-4-[(5-metiloxazol-2-karbonil)amino]pentánsav
CN106032361A (zh) * 2015-03-11 2016-10-19 齐鲁制药有限公司 Lcz-696的新晶型及其制备方法
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
AU2016236659B9 (en) * 2015-03-20 2019-05-02 Crystal Pharmatech Co., Ltd. AHU377 crystal form, preparation method and use thereof
WO2016151525A1 (en) * 2015-03-26 2016-09-29 Dr. Reddy’S Laboratories Limited Crystalline form of lcz-696
DK3294283T3 (da) 2015-05-11 2023-05-30 Novartis Ag Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
EP3307720A1 (en) 2015-06-12 2018-04-18 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
WO2016203500A2 (en) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
US11786498B2 (en) * 2015-07-02 2023-10-17 Novartis Ag Sacubitril calcium salts
CN106316973A (zh) * 2015-07-07 2017-01-11 江苏柯菲平医药股份有限公司 血管紧张素受体拮抗剂和nep抑制剂药物晶型及其制备
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN106176654A (zh) * 2015-07-11 2016-12-07 凌莉 含有化合物a的固体药物组合物及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
WO2017009784A1 (en) * 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
EP3117823A1 (en) 2015-07-17 2017-01-18 Quimica Sintetica, S.A. Amorphous solid dispersion comprising an angiotensin receptor blocker and a neutral endopeptidase inhibitor
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017013010A1 (de) 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
CN105168205A (zh) * 2015-08-18 2015-12-23 泰力特医药（湖北）有限公司 一种血管紧张素ii受体和脑啡肽酶受体双重抑制剂lcz696的制备方法
WO2017033212A1 (en) * 2015-08-26 2017-03-02 Actavis Group Ptc Ehf. Preparation of sacubitril and salt thereof and novel compounds used in the process
EP3341364B1 (en) * 2015-08-28 2023-12-20 Hetero Labs Ltd. Process for the preparation of a dual-acting angiotensin receptor-neprilysin inhibitor compound
WO2017037577A1 (en) 2015-08-28 2017-03-09 Novartis Ag New use
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN105348209B (zh) 2015-12-09 2017-12-26 浙江天宇药业股份有限公司 一种抗心衰药lcz696的制备方法
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
CN105622535B (zh) * 2015-12-28 2018-08-03 重庆两江药物研发中心有限公司 一种lcz696的制备方法
KR102150383B1 (ko) * 2016-01-20 2020-09-02 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 안지오텐신 ii 수용체 길항제 대사물질과 nep 억제제의 화합물, 및 이의 제조 방법
CN105646384A (zh) * 2016-01-27 2016-06-08 北京沃邦医药科技有限公司 一种脑啡肽酶抑制剂与血管紧张素ⅱ受体拮抗剂共晶化合物的精制方法
CA3010778C (en) * 2016-02-03 2024-02-27 Novartis Ag Galenic formulations of organic compounds
CN107033094A (zh) * 2016-02-04 2017-08-11 南京卡文迪许生物工程技术有限公司 一种药物共晶的晶型及其制备方法和组合物
WO2017141193A1 (en) * 2016-02-16 2017-08-24 Sun Pharmaceutical Industries Limited Process for the preparation of sacubitril or salts thereof
WO2017154017A1 (en) * 2016-03-07 2017-09-14 Msn Laboratories Limited Process for the preparation of trisodium (4-{[1s,3r)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tetrazol-1-id-5-yl)[1,1'-biphenyl]-4-yl]methyl}- l-valinate) and its polymorphs thereof
CA3015505C (en) 2016-03-08 2024-03-05 Theravance Biopharma R&D Ip, Llc Crystalline (2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
WO2017191619A2 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A process for the preparation of a salt of sacubitril and valsartan
EP3248592A1 (en) 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems
CN109415308B (zh) 2016-07-05 2022-09-06 诺华股份有限公司 用于早期沙卡布曲中间体的新方法
CN108619138B (zh) * 2016-08-01 2020-07-03 珠海赛隆药业股份有限公司（长沙）医药研发中心 血管紧张素受体拮抗剂和脑啡肽酶抑制剂的复合物及其用途
US10851059B2 (en) 2016-08-17 2020-12-01 Novartis Ag Processes and intermediates for NEP inhibitor synthesis
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
WO2018069833A1 (en) * 2016-10-10 2018-04-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
AU2017349757A1 (en) 2016-10-28 2019-05-30 Biocon Limited Amorphous trisodium sacubitril valsartan and process for its preparation
CN106518709A (zh) * 2016-11-07 2017-03-22 济南益新医药技术有限公司 一种无定形沙库比曲缬沙坦钠盐复合物的制备方法
WO2018119178A1 (en) * 2016-12-23 2018-06-28 StemBios Technologies, Inc. Use of somatic stem cells for decreasing neprilysin level
JP7138106B2 (ja) 2016-12-23 2022-09-15 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
CN106674206B (zh) * 2016-12-30 2021-01-19 顾国明 一种治疗心衰的共晶体药物
CN111592500A (zh) * 2017-01-03 2020-08-28 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) * 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
CN107935958B (zh) * 2017-11-30 2021-02-09 中国药科大学 一种缬沙坦葛根素钠盐复合物及其制备方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US10555412B2 (en) 2018-05-10 2020-02-04 Applied Materials, Inc. Method of controlling ion energy distribution using a pulse generator with a current-return output stage
WO2019239432A1 (en) 2018-06-14 2019-12-19 Cipla Limited Trisodium sacubitril valsartan complex and hot-melt extruded pharmaceutical composition comprising thereof
GB201810326D0 (en) 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
CA3110152A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109265406B (zh) * 2018-09-03 2020-09-22 石药集团中奇制药技术（石家庄）有限公司 一种沙库巴曲缬沙坦钠新晶型及其制备方法和用途
US11476145B2 (en) 2018-11-20 2022-10-18 Applied Materials, Inc. Automatic ESC bias compensation when using pulsed DC bias
KR20200073676A (ko) 2018-12-14 2020-06-24 엠에프씨 주식회사 발사탄 및 사쿠비트릴을 포함하는 고체 분산체 및 이를 포함하는 약학 조성물 및 이의 제조 방법
JP7451540B2 (ja) 2019-01-22 2024-03-18 アプライド マテリアルズ インコーポレイテッド パルス状電圧波形を制御するためのフィードバックループ
US11508554B2 (en) 2019-01-24 2022-11-22 Applied Materials, Inc. High voltage filter assembly
CN109912525A (zh) * 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法
KR102543230B1 (ko) 2019-05-24 2023-06-14 주식회사 파마코스텍 발사르탄/사쿠비트릴 3소듐염 수화물의 결정형 및 그 제조방법
WO2020238884A1 (zh) * 2019-05-30 2020-12-03 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
US20220226285A1 (en) * 2019-05-30 2022-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
CN113286585B (zh) 2019-09-20 2022-11-08 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
CN114945564B (zh) * 2020-01-19 2023-06-30 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
KR102149125B1 (ko) 2020-02-05 2020-08-28 유니셀랩 주식회사 새로운 사쿠비트릴 칼슘/발사르탄 공동무정형
KR20200020746A (ko) 2020-02-07 2020-02-26 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
KR20210101164A (ko) 2020-02-07 2021-08-18 보령제약 주식회사 하이브리드 화합물 및 그 제조방법
CN111253330B (zh) * 2020-02-29 2023-01-24 广州白云山天心制药股份有限公司 沙坦类药物的新晶型及其制备方法和用途
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR102155474B1 (ko) 2020-04-28 2020-09-11 유니셀랩 주식회사 사쿠비트릴/발사르탄 공동무정형
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
CN116036079A (zh) * 2020-06-18 2023-05-02 深圳信立泰药业股份有限公司 一种复合物的药物组合物及其制备方法
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
KR102215623B1 (ko) 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태
US11462388B2 (en) 2020-07-31 2022-10-04 Applied Materials, Inc. Plasma processing assembly using pulsed-voltage and radio-frequency power
TW202228677A (zh) * 2020-08-17 2022-08-01 大陸商深圳信立泰藥業股份有限公司 血管收縮素ｉｉ受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用
KR20220047076A (ko) 2020-10-08 2022-04-15 한미약품 주식회사 사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제
US11798790B2 (en) 2020-11-16 2023-10-24 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
US11901157B2 (en) 2020-11-16 2024-02-13 Applied Materials, Inc. Apparatus and methods for controlling ion energy distribution
WO2022111493A1 (zh) * 2020-11-25 2022-06-02 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物预防和/或治疗肾病的药物用途
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법
US11495470B1 (en) 2021-04-16 2022-11-08 Applied Materials, Inc. Method of enhancing etching selectivity using a pulsed plasma
WO2022224274A1 (en) 2021-04-20 2022-10-27 Mylan Laboratories Limited Polymorphic forms of sacubitril-telmisartan (1:1)
US11948780B2 (en) 2021-05-12 2024-04-02 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11791138B2 (en) 2021-05-12 2023-10-17 Applied Materials, Inc. Automatic electrostatic chuck bias compensation during plasma processing
US11967483B2 (en) 2021-06-02 2024-04-23 Applied Materials, Inc. Plasma excitation with ion energy control
US11984306B2 (en) 2021-06-09 2024-05-14 Applied Materials, Inc. Plasma chamber and chamber component cleaning methods
US11810760B2 (en) 2021-06-16 2023-11-07 Applied Materials, Inc. Apparatus and method of ion current compensation
US11569066B2 (en) 2021-06-23 2023-01-31 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US11776788B2 (en) 2021-06-28 2023-10-03 Applied Materials, Inc. Pulsed voltage boost for substrate processing
KR20230016144A (ko) 2021-07-22 2023-02-01 대봉엘에스 주식회사 사쿠비트릴 공결정과 발사르탄의 공동무정형
KR102399717B1 (ko) 2021-08-10 2022-05-19 대봉엘에스 주식회사 사쿠비트릴 및 아질사르탄 복합 약제학적 조성물, 및 이의 제조방법
US11476090B1 (en) 2021-08-24 2022-10-18 Applied Materials, Inc. Voltage pulse time-domain multiplexing
JP2024529777A (ja) * 2021-08-26 2024-08-08 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用
US12106938B2 (en) 2021-09-14 2024-10-01 Applied Materials, Inc. Distortion current mitigation in a radio frequency plasma processing chamber
US11972924B2 (en) 2022-06-08 2024-04-30 Applied Materials, Inc. Pulsed voltage source for plasma processing applications
US12111341B2 (en) 2022-10-05 2024-10-08 Applied Materials, Inc. In-situ electric field detection method and apparatus

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2499058A (en) 1950-02-28 B-haloxantfflne salts of diarylalkyl
US1954909A (en) 1929-11-14 1934-04-17 Adler Oscar Processes for the producing of molecular compounds of the salts of phenyl-quinolinecarboxylic acids with alkylated pyrazolones and alkylated amino-pyrazolones
NL76613C (el) 1948-07-01
US2534813A (en) 1950-01-21 1950-12-19 Searle & Co 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US3057731A (en) 1958-03-27 1962-10-09 Skanska Attikfabriken Ab Preparation of bakery products
AU538751B2 (en) 1979-08-20 1984-08-23 Abbott Laboratories Complex valproate salts
US4610816A (en) 1980-12-18 1986-09-09 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
DE3116334A1 (de) * 1981-04-24 1982-11-18 Gefra B.V.,, s'Gravenzande "vorrichtung zum befestigen einer seitenfuehrung, einer foerdereinrichtung an einer stuetze"
ZA84670B (en) 1983-01-31 1985-09-25 Merck & Co Inc Thiorphan analogs as enkephalinase and angiotensin converting enzyme inhibitors
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
US4740499A (en) 1986-07-28 1988-04-26 Monsanto Company Method of enhancing the bioactivity of atrial peptides
GB8811873D0 (en) 1988-05-19 1988-06-22 Pfizer Ltd Therapeutic agents
GB8812597D0 (en) 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
GB2218983A (en) 1988-05-27 1989-11-29 Pfizer Ltd Spiro-substituted glutaramides as diuretics
EP0361365A1 (en) 1988-09-30 1990-04-04 E.R. SQUIBB & SONS, INC. Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use
GB8903740D0 (en) 1989-02-18 1989-04-05 Pfizer Ltd Therapeutic agents
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
FR2658571B1 (el) 1990-02-21 1992-04-24 Bendix Europ Services Tech
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
HUT59656A (en) 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
AU1870292A (en) 1991-04-16 1992-11-17 Schering Corporation Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5273990A (en) 1992-09-03 1993-12-28 Ciba-Geigy Corporation Phosphono substituted tetrazole derivatives
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
GB9123353D0 (en) 1991-11-04 1991-12-18 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1993010773A1 (en) 1991-12-06 1993-06-10 Schering-Plough S.P.A. Use of neutral endopeptidase inhibitors in the treatment of left ventricular hypertrophy
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5376293A (en) 1992-09-14 1994-12-27 State Of South Dakota As Represented By The Department Of Transportation Deicer
DE4233296C1 (de) 1992-10-02 1994-03-31 Heitland Und Petre Int Gmbh Behälter für Kosmetikprodukte
WO1994015908A1 (en) 1993-01-14 1994-07-21 Yoshitomi Pharmaceutical Industries, Ltd. Propionamide derivative and medicinal use thereof
JPH06234754A (ja) 1993-02-10 1994-08-23 Dai Ichi Seiyaku Co Ltd 複素環式カルボン酸誘導体
CN1046119C (zh) 1993-07-22 1999-11-03 中国科学院广州电子技术研究所 聚磷酸盐复盐及其制造方法
IT1266571B1 (it) 1993-07-30 1997-01-09 Zambon Spa Derivati della beta-mercapto-propanammide utili nel trattamento delle malattie cardiovascolari
JP2810302B2 (ja) 1993-10-01 1998-10-15 ティーディーケイ株式会社 小型ポンプ
JP3576193B2 (ja) 1993-12-03 2004-10-13 第一製薬株式会社 ビフェニルメチル置換バレリルアミド誘導体
CA2168066A1 (en) 1995-02-08 1996-08-09 James R. Powell Treatment of hypertension and congestive heart failure
US6558699B2 (en) 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
PT1087775E (pt) 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
ID27664A (id) 1998-07-10 2001-04-19 Novartis Ag Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium
CN1069647C (zh) 1998-08-31 2001-08-15 靳广毅 一种具有广谱抗菌作用的化合物及其用途
IL145947A0 (en) 1999-05-27 2002-07-25 Pfizer Prod Inc Mutual prodrugs of amlodipine and atrovastatin
HN2000000050A (es) 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
CA2405496A1 (en) 2000-04-03 2001-10-11 Richard A. Reeves Vasopeptidase inhibitors to treat isolated systolic hypertension
RU2275363C2 (ru) * 2000-07-19 2006-04-27 Новартис Аг Соли валсартана, фармацевтическая композиция на их основе и способ получения солей
DE10050246C1 (de) 2000-10-11 2002-06-20 Nutrinova Gmbh Calciumdoppelsalze, Verfahren zu ihrer Herstellung und ihre Verwendung zur Konservierung
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US6777443B2 (en) 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
BR0213357A (pt) 2001-10-18 2004-10-26 Novartis Ag Compostos orgânicos
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003223637A1 (en) 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
TWI299663B (en) 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
ES2369216T3 (es) 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CN1159313C (zh) 2002-08-27 2004-07-28 何广卫 地洛他定多元酸碱金属或碱土金属盐复合盐及其药用组合物
GB0230025D0 (en) 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
CA2513746C (en) 2003-02-28 2012-08-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
AU2003223106A1 (en) 2003-03-31 2004-10-25 Hetero Drugs Limited A novel amorphous form of valsartan
CN1247596C (zh) 2003-05-15 2006-03-29 中国药品生物制品检定所 一种具有螯合结晶水合物的头孢菌素及其制备方法
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
WO2005049587A1 (en) 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
CN1246482C (zh) 2004-05-08 2006-03-22 山东大学齐鲁医院 单个核细胞白细胞相容性抗原a和b特异核糖核酸检测方法
CN1279045C (zh) 2004-07-30 2006-10-11 广州白云山制药股份有限公司 头孢硫脒复盐及其制造方法
CN100500669C (zh) 2004-12-10 2009-06-17 山东大学 一种丹酚酸黄连素复盐及其制备方法与应用
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
JP2006234754A (ja) 2005-02-28 2006-09-07 Tokyo Keiso Co Ltd 超音波流量計
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100391961C (zh) 2005-11-16 2008-06-04 天津大学 五水头孢唑林钠晶体结构及晶体分子组装制备方法
JP2007157459A (ja) 2005-12-02 2007-06-21 Sony Corp 非水電解質電池
WO2016037552A1 (zh) 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
CN105503760A (zh) * 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN110922366B (zh) * 2014-12-08 2023-02-03 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
US10562866B2 (en) 2015-02-06 2020-02-18 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
AU2016236659B9 (en) 2015-03-20 2019-05-02 Crystal Pharmatech Co., Ltd. AHU377 crystal form, preparation method and use thereof
EP3307720A1 (en) 2015-06-12 2018-04-18 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
CN105037289B (zh) 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
WO2017042700A1 (en) 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
WO2017154017A1 (en) 2016-03-07 2017-09-14 Msn Laboratories Limited Process for the preparation of trisodium (4-{[1s,3r)-1-([1,1'-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(n-pentanoyl-n-{[2'-(1h-tetrazol-1-id-5-yl)[1,1'-biphenyl]-4-yl]methyl}- l-valinate) and its polymorphs thereof
WO2018069833A1 (en) 2016-10-10 2018-04-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
CN111592500A (zh) 2017-01-03 2020-08-28 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用
CN109912525A (zh) 2019-03-13 2019-06-21 陈文辉 一种lcz696新晶型及其制备方法

Also Published As

Publication number Publication date
FR21C1000I1 (fr) 2021-03-05
HK1175465A1 (zh) 2013-07-05
PL1948158T3 (pl) 2014-06-30
FR16C0018I2 (fr) 2017-12-08
CN101098689A (zh) 2008-01-02
HUE050870T2 (hu) 2021-01-28
SG10201402055YA (en) 2014-09-26
TWI554504B (zh) 2016-10-21
JP2008542447A (ja) 2008-11-27
BRPI0605921B8 (pt) 2021-05-25
CN102702119B (zh) 2016-01-20
PT2340828T (pt) 2020-10-19
TWI418348B (zh) 2013-12-11
HRP20140274T1 (hr) 2014-04-25
CY2021003I2 (el) 2023-11-15
US20180344679A1 (en) 2018-12-06
CY1123531T1 (el) 2021-05-05
IL219782A0 (en) 2012-06-28
NO340315B1 (no) 2017-03-27
PT1948158E (pt) 2014-04-04
NO2016008I1 (no) 2016-05-18
DK1948158T3 (en) 2014-03-10
PE20070803A1 (es) 2007-09-10
LUC00195I2 (el) 2024-10-04
MY145462A (en) 2012-02-15
MA30128B1 (fr) 2009-01-02
WO2007056546A1 (en) 2007-05-18
JP4824754B2 (ja) 2011-11-30
US11096918B2 (en) 2021-08-24
US20220331282A1 (en) 2022-10-20
CA2590511C (en) 2013-01-08
US9388134B2 (en) 2016-07-12
TNSN07264A1 (en) 2008-12-31
FR16C0018I1 (el) 2016-06-24
RU2012107219A (ru) 2013-09-10
US20190374498A1 (en) 2019-12-12
HUS2100003I1 (hu) 2021-03-01
LT2340828T (lt) 2020-11-10
SI1948158T1 (sl) 2014-04-30
TW201402111A (zh) 2014-01-16
CN101098689B (zh) 2013-02-13
BR122013025375B8 (pt) 2021-05-25
RU2503668C2 (ru) 2014-01-10
FR21C1000I2 (fr) 2024-05-24
TW200803834A (en) 2008-01-16
BRPI0605921A2 (pt) 2009-05-26
IL184027A0 (en) 2007-10-31
BRPI0605921B1 (pt) 2020-08-18
EP1948158A1 (en) 2008-07-30
ES2823749T3 (es) 2021-05-10
CN102702119A (zh) 2012-10-03
AU2006311481B2 (en) 2010-02-25
MX2007008075A (es) 2007-07-13
IL184027A (en) 2014-11-30
HUS1600025I1 (hu) 2016-06-28
AR057882A1 (es) 2007-12-26
BR122013025375B1 (pt) 2020-12-01
CY2021003I1 (el) 2021-05-05
KR101432821B1 (ko) 2014-08-26
US20200016110A1 (en) 2020-01-16
PE20190374A1 (es) 2019-03-08
US20090156585A1 (en) 2009-06-18
HRP20201605T1 (hr) 2020-12-25
US20190374497A1 (en) 2019-12-12
SI2340828T1 (sl) 2020-11-30
EP2340828B1 (en) 2020-07-15
DK2340828T3 (da) 2020-10-12
LTC1948158I2 (lt) 2022-09-12
US20210361610A1 (en) 2021-11-25
NO2016008I2 (no) 2016-05-18
EP3685833A1 (en) 2020-07-29
JO3492B1 (ar) 2020-07-05
ECSP14019136A (es) 2015-12-31
US20200016109A1 (en) 2020-01-16
US20220257551A1 (en) 2022-08-18
KR20130116381A (ko) 2013-10-23
KR20080075055A (ko) 2008-08-14
EP2340828A1 (en) 2011-07-06
ES2449765T3 (es) 2014-03-21
NZ594006A (en) 2012-07-27
AU2006311481A1 (en) 2007-05-18
JP2011252013A (ja) 2011-12-15
KR101549318B1 (ko) 2015-09-01
NO337288B1 (no) 2016-02-29
US8877938B2 (en) 2014-11-04
HK1121371A1 (en) 2009-04-24
NZ600626A (en) 2013-11-29
CY2016014I1 (el) 2016-08-31
US20160324821A1 (en) 2016-11-10
EP1948158B1 (en) 2014-01-29
LTPA2021502I1 (lt) 2021-02-10
JP2015098485A (ja) 2015-05-28
GT200700055A (es) 2008-09-24
NO20073396L (no) 2007-09-10
US11642329B2 (en) 2023-05-09
CA2590511A1 (en) 2007-05-18
US20150057322A1 (en) 2015-02-26
NO20151656A1 (no) 2007-09-10

Similar Documents

Publication Publication Date Title
CY1115004T1 (el) Φαρμακευτικοι συνδυασμοι ενος ανταγωνιστη υποδοχεων αγγειοτασινης και ενος αναστολεα νερ
CY1112474T1 (el) Πιπεριδινικοι gpcr αγωνιστες
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DK1812895T3 (da) Stofkilde
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CY1109054T1 (el) Ρρυ αγωνιστες και χρησεις αυτων
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
CY1113188T1 (el) Τροποποιημενα fgf-21 πολυπεπτιδια και οι χρησεις τους
DK1928427T3 (da) Hidtil ukendt dosisformulering
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
DK1868579T3 (da) Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
EA201000888A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы в качестве гербицидов
ATE408599T1 (de) Tetrahydrocarbazole und derivate
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
BRPI0615163A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos de tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5
DK1776133T3 (da) Peptid-vasopressin-receptor-agonister
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
EA200801414A1 (ru) Кальцилитические соединения
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
DE602004010934D1 (de) Röntgenquelle
CL2007003613A1 (es) Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension.
BRPI0614480A2 (pt) composto, composição farmacêutica, uso do composto, e, métodos para tratamento de distúrbios mediados por mglur5 e para inibição da ativação de receptores de mglur5